• OPEN AN ACCOUNT
Indian Indices
Sensex
77,540.83 3.11
( 0.00%)
Global Indices
Nasdaq
53,294.39 514.18
(0.97%)
Dow Jones
7,693.51 31.35
(0.41%)
Hang Seng
65,893.13 -323.66
(-0.49%)
Nikkei 225
10,809.01 60.85
(0.57%)
Forex
USD-INR
95.67 0.05
(0.05%)
EUR-INR
111.76 0.57
(0.51%)
GBP-INR
130.35 0.55
(0.42%)
JPY-INR
0.60 0.00
(0.11%)

EQUITY - MARKET SCREENER

Jubilant Pharmova Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
530019
INE700A01033
145.1556811
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
JUBLPHARMA
444.02
14004.86
EPS(TTM)
Face Value()
Div & Yield %
1.98
1
0.57
 

SEPC Q4 PAT jumps 37% YoY to Rs 14 cr
May 25,2026
Profit before exceptional items and tax stood at Rs 15.27 crore in Q4 FY26, compared with Rs 10.02 crore in Q4 FY25. The company reported an exceptional item of Rs 0.40 crore during the quarter.

Total expenses jumped 135.75% to Rs 273.68 crore in Q4 FY26 from Rs 116.09 crore in Q4 FY25. The cost of material consumed stood at Rs 239.12 crore (up 187.68% YoY), employee benefit expenses were at Rs 6.80 crore (up 17.8% YoY), and finance costs were at Rs 9.13 crore (down 26.13% YoY) during the period under review.

SEPC is engaged in providing end-to-end solutions to engineering challenges, offering multidisciplinary design, engineering, procurement, construction, and project management services.

Shares of SEPC rose 0.64% to close at Rs 7.87 on the BSE.